Skip to main content
Premium Trial:

Request an Annual Quote

Decode, Illumina to Co-develop, Sell Molecular Diagnostics

NEW YORK, May 15 (GenomeWeb News) - Decode Genetics and Illumina plan to co-develop and commercialize DNA-based diagnostics in several major disease areas, the firms said today.

 

According to the firms, the partnership will use Illumina's platform for high-multiplex SNP-genotyping to develop diagnostics for gene variants that Decode has shown to be risk factors for various diseases.

 

Under the terms of the agreement, Illumina will gain access to disease-related biomarkers, which will be jointly validated as diagnostic panels. Illumina will market and sell these on its forthcoming BeadXpress platform, the partners said.

 

Illumina will also install its SNP-genotyping platform at Decode's labs in Iceland.

 

Initially, the companies will focus on the gene encoding leukotriene A4 hydrolase, which has been linked to heart attack; the gene encoding transcription factor 7-like 2, which is linked to type II diabetes; and the gene encoding BARD1, which is linked to breast cancer.

 

The companies will share development costs and split the profits from sales of the diagnostics tests.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.